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Articles
Correlates of HIV RNA concentrations in cerebrospinal fluid 
during antiretroviral therapy: a longitudinal cohort study
Alessandro Livelli, Florin Vaida, Ronald J Ellis, Qing Ma, Micol Ferrara, David B Clifford, Ann C Collier, Benjamin B Gelman, Christina M Marra, 
Justin C McArthur, J Allen McCutchan, Susan Morgello, Ned Sacktor, David M Simpson, Igor Grant, and Scott L Letendre for the CHARTER Group*
Summary
Background Few large projects have evaluated the factors that influence the HIV RNA concentrations (viral load) in 
cerebrospinal fluid (CSF) during antiretroviral therapy (ART) over time. We aimed to determine the correlates of HIV 
RNA in CSF in a large cohort.
Methods We analysed longitudinal data from adults living with HIV in the US CHARTER cohort. Participants in the 
CHARTER study were recruited from six US academic medical centres—in Baltimore (MD), Galveston (TX), 
New York (NY), St Louis (MO), San Diego (C92A), and Seattle (WA). Participants in this study had been assessed at 
least three times between Sept 4, 2003, and Sept 14, 2010, and were taking ART and underwent venous and lumbar 
puncture with measurement of HIV RNA concentration at all assessments. The lower limit of quantification of the 
HIV RNA assays was 50 copies per mL. Data were analysed with longitudinal mixed effects logistic regression to 
identify correlates of HIV RNA concentration (as a binary [detectable or not] and as a continuous variable) in CSF over 
time. We tested demographic characteristics, plasma HIV RNA, nadir and current CD4 cell count in blood, current 
CD8 cell count in blood, estimated duration of HIV infection, AIDS diagnosis, duration of ART, adherence to ART, 
ART characteristics, and CSF characteristics as potential correlates.
Findings At the time of analysis, 2207 assessments from 401 participants met the criteria for inclusion in this study. 
Mean duration of observation was 33·7 months (range 12–84). HIV RNA concentrations in 710 (32·2%) plasma 
specimens and in 255 (11·6%) CSF specimens were greater than the lower limit of quantification. The best multivariate 
model of HIV RNA concentration in CSF greater than the lower limit of quantification over time included increased 
plasma HIV RNA concentration (odds ratio 18·0 per 1 log10 copy per mL, 95% CI 11·3 to 28·8; p<0·0001), increased 
CSF leucocyte count (2·01 per 5 cells per μL, 1·61 to 2·39; p<0·0001), decreased CD4 cell count (0·53 per 5 square-
root cells per μL, 0·35 to 0·79; p=0·0025), decreased CNS penetration-effectiveness value (0·71 per unit, 0·56 to 0·92; 
p=0·0078), increased CD8 cell count (1·51 per 5 square-root cells, 1·11 to 2·06; p=0·0089), and protease inhibitor use 
(3·26, 1·04 to 10·23; p=0·039; model R²=0·22, p<0·0001). Analyses of continuous HIV RNA concentration in CSF 
that accounted for censoring below the lower limit of quantification had similar findings, although increased HIV 
RNA concentrations in CSF were also associated with black ethnicity (change in log10 HIV RNA concentration in CSF 
0·205, 0·0367 to 0·3733; p=0·017), increased total protein in CSF (0·0025, –0·0002 to 0·0052; p=0·069), and the 
presence of addictive-drug metabolites in urine (0·103, –0·013 to 0·219; p=0·081).
Interpretation The identified correlates of HIV RNA concentration in CSF during ART could strengthen clinical prediction 
of risk for failure to achieve or maintain HIV RNA suppression in CSF. Because most participants in this analysis were 
ART-experienced and were taking a three-drug regimen that did not include an integrase inhibitor, future research should 
focus on participants who are taking their first ART regimens or regimens that include integrase inhibitors or two drugs.
Funding The work was supported by the National Institute of Mental Health and the National Institute of Neurological 
Disorders and Stroke.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Combination antiretroviral therapy (ART) suppresses 
HIV RNA in the cerebrospinal fluid (CSF) in most 
patients but persistently detectable HIV RNA during 
ART has been linked to the risk for HIV-associated 
neurocognitive disorder (HAND)1 and depression.2 For 
example, early analyses identified that higher HIV RNA 
concentrations in CSF, but not in plasma, were associated 
with HAND.3–5 Specifically, elevated HIV RNA 
concentrations in CSF predicted impairment in the 
domains of learning, motor, attention, and working 
memory function.6 Analyses in the era of potent 
combination ART, however, have generally found 
weakened associations between HIV RNA con centration 
in CSF and neurocognitive outcomes7.
HIV RNA in CSF might also be important for other 
reasons. First, low concentrations of HIV RNA in CSF 
could lead to inflammation in the CNS.8 Second, HIV 
RNA in CSF could indicate viral escape in the CNS, 
which occurs in about 5% of otherwise effectively treated 
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adults and can be associated with neurological 
symptoms.9,10 Third, failure to suppress HIV RNA fully in 
CSF could lead to development of drug-resistance 
mutations and limit the potential for a functional HIV 
cure. Finally, HIV RNA concentrations in CSF might 
reflect those in brain tissue and thus might be useful for 
studies that are focused on eradicating HIV.
Although many studies of HIV RNA in CSF have been 
published (appendix), they were either cross-sectional in 
design or had relatively modest sample sizes. Large, 
longitudinal analyses are better suited for inferring 
causality than smaller, cross-sectional ones. An 
observational cohort, CNS HIV AntiRetroviral Therapy 
Effects Research (CHARTER), sampled CSF in a large 
number of volunteers over several years, enabling such 
analyses.6 Our objective was to understand the correlates 
of HIV RNA concentration in CSF over time in adults 
who are taking ART. We hypothesised that multiple 
characteristics, including HIV RNA in plasma and esti-
mated drug distribution in the CNS, would be associated 
with HIV RNA concentration in CSF over time.
Methods
Study design
The CHARTER study is a six-site, prospective, obser- 
vational study that was designed to comprehensively 
assess a representative clinical population of adults living 
with HIV in the USA. The six sites were in Baltimore 
(MD), Galveston (TX), New York (NY), St Louis (MO), 
San Diego (CA), and Seattle (WA). All sites were based at 
US academic medical centres and were selected by a 
competitive, peer-review process. Participants were 
recruited from the clinics located at these US academic 
medical centres and via community centres, advocacy 
groups, and community advisory boards.
Study population
We analysed data from all participants in the US 
CHARTER cohort who underwent at least 3 semi-annual 
assessments between Sept 4, 2003, and Sept 14, 2010; 
reported use of ART at all visits; successfully underwent 
venous and lumbar puncture; and had HIV RNA 
concentration measured in collected blood and CSF. 
The Institutional Review Board at each site approved 
all study procedures and all participants provided written 
informed consent.
Procedures
Comprehensive neuromedical assessments were done, 
including medical and treatment history, physical 
examination, and venous and lumbar puncture. 
Participants were assessed by investigators or trained 
study personnel. All participants underwent all 
assessments at each visit with the exception of lumbar 
puncture (not all participants consented) and neuro-
imaging (done in only a subgroup by design). 
ART drug distribution into the CNS was estimated by 
the CNS penetration-effectiveness method.11 ART non-
adherence was estimated by self-report of taking fewer 
than 95% of doses in the 4 days before assessment 
(AIDS Clinical Trials Group 4-day method). HIV RNA 
was quantified by commercial RT-PCR (Amplicor 
For the CHARTER study website 
see https://charternntc.org
Research in context
Evidence before this study
Before doing this study, we considered the extent of previously 
published data on the correlates of HIV RNA concentrations in 
cerebrospinal fluid (CSF) in adults living with HIV and taking 
combination antiretroviral therapy (ART). We searched PubMed 
for analyses of longitudinal data published between Jan 1, 2002, 
and Dec 31, 2017, using terms “HIV RNA” AND “cerebrospinal 
fluid” AND “antiretroviral” AND “adult” AND “longitudinal” NOT 
“opportunistic” NOT “monotherapy”. The results of our search are 
summarised in the appendix. In brief, many of these longitudinal 
studies focused on the change in HIV RNA in CSF in response to 
ART and some identified correlates of HIV RNA in CSF over time, 
which included HIV RNA in plasma, CD4 cell count, duration of 
ART, and characteristics of the ART regimen. A separate, large 
analysis from our group focused solely on cross-sectional data 
and confirmed some of these correlates of HIV RNA in CSF 
(eg, HIV RNA in plasma and ART characteristics) and also 
identified other contributors (eg, race and depression).
Added value of this study
The publications we found in our search (appendix) have a 
mean sample size of 41 participants. By contrast, this Article 
summarises longitudinal data from more than 2200 lumbar 
puncture samples from nearly ten times as many participants 
(n=401), which adds substantially to the existing HIV 
literature. In addition to confirming previous findings linking 
HIV RNA levels in CSF to HIV RNA levels in plasma, CSF 
leukocyte number, and ART drug characteristics (eg, number 
of neuroactive drugs), we found evidence of associations with 
CD4 and CD8 cell counts. This finding adds to mounting 
evidence linking the low ratio of these T-cell subsets to 
persistent immune dysfunction, reservoir size, and 
complications in adults living with HIV during ART.
Implications of all the available evidence
The longitudinal data in this Article strengthen existing data 
from previous small studies. With the increasing recognition 
that CSF viral escape occurs in about 5% of treated adults living 
with HIV, our findings might help identify patients at risk for 
CSF viral escape and other complications of the CNS in the 
clinic. The data could also have implications for efforts to 
eradicate HIV from the CNS.
See Online for appendix
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version 1.5, Roche Diagnostics, Indianapolis, IN, USA; 
lower limit of quantification 50 copies per mL).  Other 
biomarkers (eg, CD4 cell count, electrolytes, complete 
blood count, and CSF leucocytes) were measured by 
routine clinical methods. Nadir CD4 cell count was 
defined as the lowest value of either self-reported count 
or study measurement. HIV-associated neurocognitive 
disorders were diagnosed according to the Frascati 
criteria.12 All participants completed the Beck Depression 
Inventory and major depression was diagnosed by 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) criteria.
Statistical analysis
Because all participants were taking ART, the distri-
bution of HIV RNA in CSF was highly skewed with 
many tied, undetectable values. For this reason, HIV 
RNA concentration in CSF was analysed by two 
methods. First, we analysed HIV RNA in CSF as a 
binary variable (greater than the lower limit of 
quantification [detectable] or less than or equal to the 
lower limit of quantification [undetectable]) using 
longitudinal modelling with logistic regression. Then, 
we analysed HIV RNA in CSF as a continuous variable 
and accounting for censoring below the limit of 
detection by a published method13 using linear mixed 
models. We screened demographic, HIV disease, 
treatment, and CSF characteristics, for inclusion in 
multivariate models by using individual mixed effects 
models. Candidate covariates were selected for 
multivariate analysis using an α of 0·10. Multivariate 
analysis was then done, also using longitudinal mixed 
effects logistic regression. When the distribution of 
independent variables were highly skewed, we trans-
formed them to reduce skewness (eg, log10 
transformation of plasma HIV RNA and square-root 
transformation of cell counts). Regression-derived 
estimates were converted to odds ratios (ORs) to ease 
interpretation. For this same reason, ORs were adjusted 
for plasma HIV RNA (per 1 log10 copies per mL) and cell 
counts (per 5 square-root cells). Correlation within 
participants was modelled via a participant-specific 
random effect. We built multivariate models with 
backward elimination with the goal of deriving a concise 
combination of predictors based on maximal explanatory 
value after eliminating variables that did not contribute 
to a better fit.
Data were analysed using R statistical software program 
(version 3.1.1), including the Imec package.
Role of the funding source
The funder of the study played no role in study design, 
data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author and 
the principal investigator had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
At the time of analysis, 2207 assessments from 
401 participants met the criteria for inclusion in this 
study. At first visit, participants were mostly middle-aged 
(mean 44 years [SD 8·2]) men (318 [79%] of 401) who 
reported their ethnicity as either black (176 [44%]) or 
white (170 [42%]). 286 (71%) participants had been 
diagnosed with AIDS. Median nadir CD4 cell count was 
135 cells per µL (IQR 28–243) and median CD4 cell count 
was 446 cells per µL (276–635). 109 (27%) participants 
were seropositive for hepatitis C virus (table 1).
(n=401)
Demographics and other characteristics
Age (years) 44 (8·2)
Sex
Female 83 (21%)
Male 318 (79%)
Ethnicity
Black 176 (44%)
White 170 (42%)
Hispanic 45 (11%)
Other 10 (2%)
Disease and treatment characteristics
Plasma HIV RNA concentration ≤50 copies per mL 240 (60%)
CD4 count (cells per µL) 446 (276–635)
CD8 count (cells per µL) 867·5 (628–1170)
Nadir CD4 cell count (cells per µL) 135 (28–243)
Duration of HIV disease, months 143·0 (68–189)
AIDS diagnosis 286 (71%)
Number of current antiretroviral drugs 3·2 (1–6)
Duration of ART, months 18·0 (7·6–34·2)
CPE of current regimen 7·5 (2·02)
Current protease inhibitor use 242 (60%)
Number of past antiretroviral drugs 3 (1–6)
Adherence >95% 351 (88%)
HCV seropositive 109 (27%)
CSF characteristics
CSF white blood cells (cells per µL) 2 (1–4)
CSF protein (mg/dL) 42 (33–53)
CSF HIV RNA concentration ≤50 copies per mL 347 (87%)
HAND and depression characteristics
HAND diagnosis
Unimpaired 206 (51%)
Asymptomatic neurocognitive impairment 114 (28%)
Mild neurocognitive disorder 34 (8%)
HIV-associated dementia 8 (2%)
Impaired because of a cause other than HIV 39 (10%)
Major depression
Baseline 49 (12%)
Lifetime 184 (46%)
Data are n (%), median (IQR), or mean (SD). ART=antiretroviral therapy. 
CPE=central nervous system penetration effectiveness. HCV=hepatitis C virus. 
CSF=cerebrospinal fluid. HAND=HIV-associated neurocognitive disorder. 
Table 1: Baseline characteristics at first visit
For the Beck Depression 
Inventory see https://
beckinstitute.org/get-informed/
tools-and-resources/
professionals/patient-
assessment-tools/ 
For the DSM-IV see https://www.
psychiatry.org/psychiatrists/
practice/dsm
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The mean duration of observation was 33·7 months 
(range 12–84). The mean number of lumbar punctures 
per subject was 5·3 (SD 3·0). All participants reported 
ART use at all visits. For all visits combined, the median 
duration of the current (ie, at the time of each visit) ART 
regimen was 18·0 months (IQR 7·6–34·2). 282 (70·3%) 
participants took ART regimens containing three drugs 
and 89 (22%) were taking their first regimen. The most 
common regimens across all 2207 visits were efavirenz, 
tenofovir, and emtricitabine (378 visits [17·1%]), ritonavir-
boosted atazanavir, tenofovir, and emtricitabine 
(363 [16·4%]), ritonavir-boosted lopinavir, tenofovir, and 
emtricitabine (115 [5·2%]), and efavirenz, abacavir, and 
lamivudine (62 [2·8%]). The most common individual 
drugs were tenofovir (1681 [76·2%]), low-dose ritonavir 
(1394 [63·2%]), emtricitabine (1209 [54·8%]), lamivudine 
(1054 [47·8%]), atazanavir (787 [35·7%]), efavirenz 
(706 [32·0%]), abacavir (667 [30·2%]), zidovudine 
(512 [23·2%]), and lopinavir (433 [19·6%]). Raltegravir 
was used at 67 visits (3·0%). The median CNS 
penetration-effectiveness value was 7 (IQR 6–9).
HIV RNA concentrations were undetectable in plasma 
at 1444 (65·4%) of 2207 visits and in CSF at 1955 (88·6%) 
visits. When HIV RNA concentrations were detectable in 
plasma, the median value was 544 copies per mL 
(IQR 137–7265). When HIV RNA concentrations were 
detectable in CSF, the median value was 535 copies per 
mL (145–2498).
In analyses of the binary CSF HIV RNA (detectable vs 
undetectable) over time, screening analyses identified 
15 variables that were associated with the outcome, the 
strongest of which was HIV RNA in plasma (OR 19·7, 
95% CI 12·8–30·5; p<0·0001; figure; table 2). Variables 
that had p values greater than 0·10 with HIV RNA in 
CSF over time included sex, AIDS, current or lifetime 
depression, nadir CD4 cell count, duration of HIV 
infection, hepatitis C virus serostatus, and CSF 
erythrocyte number.
The best multivariate mixed effects model included 
six covariates (table 2). In descending order of effect 
size, the covariates of detectable HIV RNA in CSF 
were increased HIV RNA concentrations in plasma 
(OR 18·0 per 1 log10 copies per mL, 95% CI 11·3–28·8), 
protease inhibitor use (3·26, 1·04–10·23), increased CSF 
leucocyte number (2·01 per 5 cells per µL, 1·61–2·39), 
decreased CD4 cell count (0·53 per 5 square-root 
cells per µL, 0·35–0·79), increased CD8 cell count 
(1·51 per 5 square-root cells per µL, 1·11–2·06), and 
decreased CNS penetration-effectiveness value (0·71 per 
unit, 0·56–0·92; model R²=0·22, p<0·0001). 
When a binary transformation of CNS penetration 
effectiveness (CNS penetration effectiveness ≤ or > than 
the median value of 7) was included in the model instead 
of the untransformed value, protease inhibitor use was 
no longer significantly associated with HIV RNA in CSF 
over time.
In analyses of continuous HIV RNA in CSF that 
accounted for censoring below the lower limit of 
quantification (table 3), the covariates were the same 
with four exceptions: CD8 cell count was not included in 
the best multivariate model, whereas increased CSF total 
protein, presence of addictive drug metabolites in urine, 
and black ethnicity were (model p<0·0001).
In secondary analyses, 148 (37%) of 401 participants 
had HIV RNA concentrations in plasma of 50 copies 
per mL or less at all visits. Nine (6%) of these participants 
had HIV RNA concentrations in CSF greater than 
50 copies per mL at one or more visits, consistent with 
CSF viral escape.9 These nine participants had a total of 
63 visits and CSF viral escape occurred at 13 (21%) of 
them. Analyses of these 148 participants identified 
that CSF viral escape was associated with the presence 
of increased CSF leucocyte counts (p=0·035) across all 
visits. Limiting the analysis to the 63 visits from the nine 
participants who had a CSF viral escape event identified, 
we found that CSF viral escape was associated with both 
increased CSF leucocyte counts (p=0·029) and decreased 
CNS penetration-effectiveness values (p=0·022).
Figure: Modelled longitudinal regression curve of binary HIV RNA in CSF and 
CPE and other longitudinal correlates of binary HIV RNA in CSF
(A) Data points are point estimates (95% CI) and the solid line was modelled 
from a longitudinal analysis of the proportion of samples with HIV RNA 
concentrations of 50 copies per mL or more. (B) Significant covariates of 
binary HIV RNA concentration in CFS in the best multivariable model. 
CPE=CNS penetration effectiveness. CSF=cerebrospinal fluid. OR=odds ratio.
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Discussion
In this study, we modelled longitudinal data from 
401 adults observed over an average of 2·5 years. We 
found that several viral, immune, and treatment variables 
were associated with HIV RNA in CSF over time. As 
expected, failure to suppress HIV RNA fully in plasma 
was the most influential factor in both linear and logistic 
models of HIV RNA in CSF. Fewer CD4 cells were also 
associated with HIV RNA in CSF over time in both 
models, consistent with the known link between low 
CD4 cell count and risk of HAND.14 CD8 cells have not 
previously been clearly linked to HIV RNA in CSF, 
although reports15 of CD8 encephalitis suggest at least an 
indirect link. The combination of low CD4 and high 
CD8 cell count is consistent with a persistently inverted 
CD4-to-CD8 ratio during ART, which might be a marker 
of immune senescence,16 persistent T-cell activation,17 and 
risk for non-AIDS comorbidities.18 Our data suggest that a 
greater degree of CD4-to-CD8 ratio inversion also 
indicates increased risk for detectable HIV RNA in CSF 
during ART, which could increase the risk of CNS 
inflammation and vulnerability to HAND.19 Of note, we 
did not find an association between CD8 cells and HIV 
RNA in CSF in analyses of continuous HIV RNA 
concentration in CSF that accounted for censoring below 
the lower limit of quantification.
CSF leucocytes have long been linked to HIV RNA 
concentrations in CSF.20 Our analysis independently 
validates this historical association and further supports 
a role for leucocyte migration in CSF viral escape. The 
combination of low CD4 cell counts and high CSF 
leucocyte counts is consistent with reports linking these 
factors with greater autonomous CNS production of 
HIV21 and viral adaptation in CSF.22
Decreased estimated effectiveness of ART in the CNS 
has previously been reported to correlate with HIV RNA 
in CSF in cross-sectional analyses. Our data lend further 
support to the role of ART in the pathogenesis of CSF 
viral escape.9,23 Although ART characteristics might be 
more clearly linked to the presence of HIV RNA in CSF, 
their relation to neurocognitive disorders remains 
controversial.24 The inclusion of both CNS penetration 
effectiveness and protease inhibitor use in multivariate 
models suggests that protease inhibitors (primarily 
atazanavir, lopinavir, and ritonavir, in this analysis) might 
influence the concentration of HIV RNA in CSF by 
mechanisms that are not adequately described by the 
CNS penetration-effectiveness method. Although the 
protease inhibitor effect size was large, the confidence 
interval of the estimate was broad (OR 3·26, 95% CI 
1·04–10·23) and the effect was not selected in models 
that included a binary transformation of CNS penetration 
effectiveness (data not shown). If protease inhibitor use 
were truly clinically associated with increased HIV RNA 
concentrations in CSF, several explanations would be 
possible. Protease inhibitors can modulate molecular 
drug transporters,25 which could reduce protease 
inhibitor concentrations in the CNS in a way that is not 
captured by the CNS penetration-effectiveness method. 
Consistent with this, some studies have confirmed that 
CSF concentrations of several protease inhibitors appear 
to be lower than expected on the basis of the unbound 
fraction in blood.26 Protease inhibitors have also recently 
been linked to cerebral small vessel disease,27 which 
could alter drug distribution, adhesion molecule 
expression,28 and cell migration.29 Protease inhibitor use 
could also be an indicator of unmeasured factors, such as 
clinical channelling. For example, clinicians tend to 
choose protease inhibitors for patients who have high 
HIV RNA concentrations in blood, more advanced 
immune suppression, increased ART experience, or 
increased ART drug resistance.
Although our study was large and longitudinal, it does 
have limitations that could affect the accuracy and 
interpretation of the findings. The most important is the 
observational nature of the CHARTER study, meaning 
that ART initiation was not randomised or synchronised 
across participants, which can be a source of bias. 
Another limitation is that the analysis included 
participants who had detectable HIV RNA in plasma, 
which could reduce generalisability since suppressing 
HIV is the chief goal of ART in the clinic. However, most 
Univariable Multivariable
OR (95% CI) p value OR (95% CI) p value
HIV disease characteristics
Plasma HIV RNA (per 1 log10 counts 
per mL)
19·7 (12·8–30·5) <0·0001 18·0 (11·3–28·8) <0·0001
Current CD4 cell count (per 5 square-root 
cells per µL)
0·29 (0·21–0·40) <0·0001 0·53 (0·35–0·79) 0·0025
Current CD8 cell count (per 5 square-root 
cells per µL)
1·04 (0·81–1·31) 0·0001 1·51 (1·11–2·06) 0·0089
Treatment characteristics
CPE (per 1 unit) 0·75 (0·63–0·89) 0·0003 0·71 (0·56–0·92) 0·0078
Protease inhibitor use 2·83 (1·17–6·83) 0·0059 3·26 (1·04–10·23) 0·039
Adherence <95% doses in 
4 days before assessment
2·97 (1·49–5·94) 0·0011 ·· ··
Number of current antiretrovirals 0·62 (0·37–1·02) 0·046 ·· ··
Number of past antiretrovirals 1·14 (0·98–1·32) 0·052 ·· ··
Duration of current ART regimen (per 
1 month)
0·92 (0·83–1·03) 0·096 ·· ··
Demographics and other characteristics
Age (per 1 year) 1·06 (0·99–1·14) 0·038 ·· ··
Ethnicity (black) 5·90 (1·71–20·4) 0·0017 ·· ··
Addictive drug metabolites in urine 2·28 (1·35–3·85) 0·0024 ·· ··
Addictive drug use within previous 
30 days
2·26 (1·04–4·92) 0·041 ·· ··
CSF characteristics
CSF leucocytes (per 5 cells per µL) 1·90 (1·61–2·25) <0·0001 2·01 (1·61–2·39) <0·0001
CSF total protein (per 10 mg/L) 1·02 (1·00–1·03) 0·047 ·· ··
CSF=cerebrospinal fluid. OR=odds ratio. CPE=central nervous system penetration effectiveness. ART=antiretroviral therapy.
Table 2: Correlates of binary HIV RNA in CSF
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participants who had detectable HIV RNA in plasma had 
concentrations less than 1000 copies per mL (59·3%), 
which does not necessarily portend ART failure.30 
Focusing solely on participants taking suppressive ART 
would require that we re-assay all specimens with a more 
sensitive assay, such as a single copy assay. Another 
limitation related to the inclusion of participants who 
had detectable HIV RNA in plasma is the absence of data 
for ART drug-resistance mutations in these analyses. 
The participants were mostly ART-experienced, having 
previously used a median of five ART drugs. Detectable 
HIV RNA in CSF could be due to unmeasured ART drug 
resistance, for example, rather than other factors, such as 
CNS penetration effectiveness, which could theoretically 
be colinear with it in analyses of HIV RNA. Finally, by 
design, this analysis focused on HIV RNA in CSF, not on 
other neurological outcomes. As noted, we have 
previously reported links between increased HIV RNA in 
CSF and two common neurological complications: 
neurocognitive decline1 and incident depression.2
In this large analysis of ART users over the course of 
up to about 3·5 years, we found that HIV RNA was rarely 
detectable in CSF (<12% of visits) and that it was 
associated with several factors over time, most 
importantly high HIV RNA in plasma. The associations 
with CD4 cell counts and CSF leucocyte counts are 
consistent with previous reports,31 but the association 
with the concentration of CD8 cells is a new finding that 
might help identify patients at risk for CSF viral escape 
and neurological complications. Only two correlates, 
CNS penetration-effectiveness values and protease 
inhibitor use, were modifiable, which might have 
implications for CSF viral escape and achieving 
functional cure.
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Univariable Multivariable
Change in log10 HIV RNA 
concentration in CSF (95% CI)
p value Change in log10 HIV RNA 
concentration in CSF (95% CI)
p value
HIV disease characteristics
Plasma HIV RNA (per 1 log10 counts per mL) 0·834 (0·464 to 1·204) <0·0001 0·696 (0·364 to 1·029) <0·0001
Current CD4 cell count (per 5 square-root cells per µL) –0·518 (–0·748 to –0·289) <0·0001 –0·0925 (–0·1412 to –0·0438) 0·0002
Treatment characteristics
CPE (per 1 unit) –0·116 (–0.163 to –0·069) <0·0001 –0·0311 (–0·0587 to  –0·0035) 0·027
Protease inhibitor use 0·481 (0·248 to 0·714) 0·0001 0·219 (0·0886 to 0·3494) 0·0013
Adherence <95% doses in 4 days before assessment 0·493 (0·288 to 0·697) <0·0001 ·· ··
Number of past antiretrovirals 0·0324 (–0·013 to 0·078) 0·16 ·· ··
Number of current antiretrovirals –0·184 (–0·326 to –0·042) 0·011 ·· ··
Demographics and other characteristics
Age (per 1 year) –0·0261 (–0·047 to –0·005) 0·014 ·· ··
Ethnicity (black) –0·284 (–0·403 to –0·164) <0·0001 0·205 (0·0367 to 0·3733) 0·017
Addictive drug metabolites in urine 0·429 (0·240 to 0·619) <0·0001 0·103 (–0·013 to 0·219) 0·081
Addictive drug use within previous 30 days 0·393 (0·169 to 0·617) 0·0006 ·· ··
CSF characteristics
CSF leucocytes (per 5 cells per µL) 0·0389 (0·0325 to 0·0452) <0·0001 0·0247 (0·0133 to 0·0361) <0·0001
CSF total protein (per 10 mg/L) 0·00916 (0·00479 to 0·01353) <0·0001 0·0025 (–0·0002 to 0·0052) 0·069
CSF=cerebrospinal fluid. CPE=central nervous system penetration effectiveness.
Table 3: Correlates of continuous HIV RNA concentration in CSF accounting for censoring below the lower limit of quantitation
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